Hypha Labs (Hypha Labs) Short Interest

View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Hypha Labs's Short Interest

For the Diagnostics & Research subindustry, Hypha Labs's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hypha Labs's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Short Interest distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Short Interest falls into.

Hypha Labs (Hypha Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:DIGP) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118

Website

https://www.digipath.com

DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.

Executives

A Stone Douglass	director	10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank	director	19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda	officer: Chief Executive Officer	111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann	director	1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben	director	430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser	director	4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer	director	287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco	director	611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson	officer: Chief Financial Officer	3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner	director	28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc	10 percent owner	16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin	director, officer: President	C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee	10 percent owner	3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen	director, 10 percent owner, officer: CFO	8908 SPLITARROW DRIVE, AUSTIN TX 78717